Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase NA 3Phase 1/2 3Phase EARLY_PHASE1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Breast Neoplasms, Male 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01582009 2022-08-15

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Roswell Park Cancer Institute

Phase 1/2 Terminated
26 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT00425672 2018-12-05

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

University of Washington

Phase 1/2 Completed
15 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01105312 2017-06-27

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Completed
28 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡